Pegylated Liposomal Doxorubicin-Efficacy in Patients with Recurrent High-Grade Glioma

Cancer

Volumn 100, Issue 6, 2004, Pages 1199-1207

  Hau, Peter ^a   Fabel, Klaus ^a,b   Baumgart, Ulrike ^a   Rümmele, Petra ^a   Grauer, Oliver ^a   Bock, Annekatrin ^a   Dietmaier, Christopher ^a   Dietmaier, Wolfgang ^c   Dietrich, Jörg ^a,d   Dudel, Christine ^e   Hübner, Franz ^a   Jauch, Tanya ^a   Drechsel, Elisabeth ^a   Kleiter, Ingo ^a   Wismeth, Cäcile ^a   Zellner, Anton ^a   Brawanski, Alexander ^a   Steinbrecher, Andreas ^a   Marienhagen, Jörg ^a   Bogdahn, Ulrich ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c Fachhochschule Amberg Weiden   (Germany)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anaplastic astrocytoma; Glioblastoma; Pegylated liposomal doxorubicin; Phase II trial; Tamoxifen

Indexed keywords

DOXORUBICIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; METHYLPREDNISOLONE; PROCARBAZINE; PYRIDOXINE; TAMOXIFEN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW TOXICITY; BULLOUS SKIN DISEASE; CANCER GRADING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; EVALUATION; FEMALE; GLIOMA; HAND FOOT SYNDROME; HUMAN; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MALE; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RECURRENT CANCER; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKIN TOXICITY; STATISTICAL SIGNIFICANCE; SUPERINFECTION; TUMOR RESISTANCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DOXORUBICIN; DRUG CARRIERS; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PEPTIDES; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TAMOXIFEN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 12144291225     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20073     Document Type: Article

References (38)

1. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg. 1998;88:1-10.
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J Clin Oncol. 1999;17:2572-2578.
3. Brandes AA, Fiorentino MV. The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest. 1996;14:551-559.
4. Haroun RI, Brem H. Local drug delivery. Curr Opin Oncol. 2000;12:187-193.
5. Balmaceda C. Advances in brain tumor chemosensitivity. Curr Opin Oncol. 1998;10:194-200.
6. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H. Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol. 1999;125:481-486.
7. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg. 1995;83:1029-1037.
8. Cabanes A, Tzemach D, Goren D, Horowitz AT, Gabizon A. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res. 1998;4:499-505.
9. Vaage J, Barbera-Guillem E, Abra R, Huang A, Working P. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer. 1994;73:1478-1484.
10. Harris L, Winer E, Batist G, et al. Phase III study of TLC D-99 (liposome encapsulated doxorubicin) versus free doxorubicin in patients with metastatic breast carcinoma. J Clin Oncol. 1998;17:474.
11. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter Phase II trial. J Clin Oncol. 1997;15:3185-3191.
12. Fabel K, Dietrich J, Hau P, et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer. 2001;92:1936-1942.
13. Twentyman PR. MDR1 (P-glycoprotein) gene expression-implications for resistance modifier trials. J Natl Cancer Inst. 1992;84:1458-1460.
14. Cole SP, Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays. 1998;20:931-940.
15. Bredel M, Zentner J. Brain-tumour drug resistance: the bare essentials. Lancet Oncol. 2002;3:397-406.
16. Abe T, Mori T, Wakabayashi Y, et al. Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J Neurooncol. 1998;40:11-18.
17. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT Jr. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res. 1990;50:7134-7138.
18. Chamberlain MC, Kormanik PA. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol. 1999;56:703-708.
19. Couldwell WT, Hinton DR, Surnock AA, et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res. 1996;2:619-622.
20. Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol. 1997;24(1 Suppl 1):S1-65-S1-70.
21. Stewart DJ, Goel R, Cripps MC, Huan S, Yau J, Verma S. Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot study. Invest New Drugs. 1997;15:267-277.
22. Berman E, McBride M, Lin S, Menedez-Botet C, Tong W. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia. 1995; 9:1631-1637.
23. Waddle JR, Fine RL, Case BC, et al. Phase I and pharmacokinetic analysis of high-dose tamoxifen and chemotherapy in normal and tumor-bearing dogs. Cancer Chemother Pharmacol. 1999;44:74-80.
24. Ducharme J, Fried K, Shenouda G, Leyland-Jones B, Wainer IW. Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen. Br J Clin Pharmacol. 1997;43:189-193.
25. Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLC-C30 scoring manual (2nd edition). Brussels: European Organization for Research and Treatment of Cancer, 1999.
26. Yokogami K, Kawano H, Moriyama T, et al. Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET? Eur J Nucl Med. 1998;25:401-409.
27. Macdonald DR, Cascino TL, Schold SC Jr., Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
28. Schoenfeld DA. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika. 1981; 68:316-318.
29. Grant R, Liang BC, Slattery J, Greenberg HS, Junck L. Chemotherapy response criteria in malignant glioma. Neurology. 1997;48:1336-1340.
30. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res. 1998;4:1567-1571.
31. Yung WK, Albright RE, Olson J, et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
32. Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol. 1996;27:149-155.
33. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer. 2000;89:1037-1047.
34. Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol. 1999;17:3512-3521.
35. De Baere T, Elias D, Ducreux M, et al. [Percutaneous radiofrequency ablation of hepatic metastases. Preliminary experience]. Gastroenterol Clin Biol. 1999;23:1128-1133.
36. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs. 1997;54 Suppl 4:15-21.
37. Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol. 2000;18:1481-1491.
38. Osoba D, Northfelt DW, Budd DW, Himmelberger D. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest. 2001;19:573-580.